EMA to Review New Safety Data on Alzheimer’s Drug Leqembi
The European Medicines Agency (EMA) announced it will review new safety data on the Alzheimer’s disease drug Leqembi (lecanemab). This follows a prior decision to recommend its use in the European Union. Lecanemab is indicated for treating mild cognitive impairment and early Alzheimer’s disease. It is intended for patients withContinue Reading